Cardiovascular Diseases Therapeutics Market in Asia Pacific to 2019 – Promising Pipeline Drugs to Offset Revenue Decline from Generic Erosion and Off-Label Use...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 9
2 Introduction 10
3 Therapeutic Landscape 11
3.1 Heart Failure 11
3.1.1 Symptoms 11
3.1.2 Etiology 12
3.1.3 Pathophysiology 12
3.1.4 Co-morbidities and Complications 12
3.1.5 Diagnosis 13
3.1.6 Classification 14
3.1.7 Prognosis and Disease Staging 14
3.1.8 Treatment Options 15
3.2 Myocardial Infarction 18
3.2.1 Symptoms 18
3.2.2 Etiology 18
3.2.3 Pathophysiology 18
3.2.4 Co-morbidities and Complications 19
3.2.5 Diagnosis 19
3.2.6 Classification 20
3.2.7 Treatment Options 21
3.3 Acute Coronary Syndrome 22
3.3.1 Symptoms 22
3.3.2 Etiology 22
3.3.3 Pathophysiology 23
3.3.4 Diagnosis 23
3.3.5 Treatment Options 24
4 Marketed Products 26
4.1 Heart Failure 26
4.2 Myocardial Infarction 26
4.3 Acute Coronary Syndrome 26
4.4 Key Marketed Products 26
4.4.1 Arixtra 26
4.4.2 Brilinta 28
4.4.3 Crestor 29
4.4.4 Diovan and Diovan HCT/Co-Diovan 30
4.4.5 Atacand 30
4.4.6 Lipitor 31
4.4.7 Clopidogrel bisulfate 32
4.4.8 Angiomax 32
4.4.9 Lovenox 33
4.4.10 Norvasc 34
4.4.11 Coreg 34
4.4.12 Ivabradine 36
4.4.13 Toprol-XL 36
5 Pipeline Analysis 38
5.1 Heart Failure Pipeline 38
5.1.1 Overall Pipeline 38
5.1.2 Pipeline Analysis by Molecule Type 39
5.1.3 Pipeline Analysis by Mechanism of Action 40
5.2 Myocardial Infarction Pipeline 41
5.2.1 Overall Pipeline 41
5.2.2 Pipeline Analysis by Molecule Type 42
5.2.3 Pipeline Analysis by Mechanism of Action 43
5.3 Acute Coronary Syndrome Pipeline 44
5.3.1 Overall Pipeline 44
5.3.2 Pipeline Analysis by Molecule Type 45
5.3.3 Pipeline Analysis by Mechanism of Action 46
5.4 Promising Drug Candidates in the Pipeline 47
5.4.1 LCZ-696 47
5.4.2 Darapladib (SB-480848) 48
5.4.3 Neucardin 49
5.4.4 Cangrelor 50
5.4.5 Serelaxin (Novartis AG) 50
6 Market Forecast to 2019 51
6.1 Asia-Pacific Market 51
6.1.1 Treatment Usage Patterns 51
6.1.2 Annual Cost of Therapy 51
6.1.3 Market Size 51
6.2 Australia 53
6.2.1 Treatment Usage Patterns 53
6.2.2 Annual Cost of Therapy 53
6.2.3 Market Size 53
6.3 China 55
6.3.1 Treatment Usage Patterns 55
6.3.2 Annual Cost of Therapy 55
6.3.3 Market Size 55
6.4 Japan 57
6.4.1 Treatment Usage Patterns 57
6.4.2 Annual Cost of Therapy 57
6.4.3 Market Size 57
6.5 India 59
6.5.1 Treatment Usage Patterns 59
6.5.2 Annual Cost of Therapy 59
6.5.3 Market Size 59
6.6 Drivers and Barriers for the Global Cardiovascular Diseases Market 61
6.6.1 Drivers 61
6.6.2 Barriers 62
7 Deals and Strategic Consolidations 63
7.1 Deals Analysis 63
7.2 Major Co-Development Deals 65
7.2.1 Genzyme Enters into Agreement with Osiris Therapeutics 66
7.2.2 Les Laboratoires Servier Enters into Co-development Agreement with miRagen Therapeutics 66
7.2.3 Cytokinetics Signs Strategic Agreement with Amgen 66
7.2.4 Biogen Idec Inc. Enters into Agreement with Cardiokine Inc. 66
7.2.5 Bristol-Myers Squibb Enters into Co-Development Agreement with Ambrx Inc. 67
7.2.6 Angioblast Systems Inc. Enters into Co-Development Agreement with Abbott India Limited 67
7.3 Major Licensing Deals 68
7.3.1 Cephalon Inc. Enters into Licensing Agreement with Mesoblast Limited for Regenerative Medicine 69
7.3.2 The Medicines Company Enters into Licensing Agreement with Pfizer Inc. 69
7.3.3 BioLineRx, Ltd. Enters into Licensing Agreement With Ikaria Holdings, Inc. 69
7.3.4 KAI Pharmaceuticals, Inc. Enters into Licensing Agreement with Bristol-Myers Squibb 69
7.3.5 Theravance, Inc. Enters into Licensing Agreement with Merck & Co., Inc. for Cardiovascular Therapeutic Candidates 70
7.3.6 Novartis AG Enters into License Agreement with Portola Pharmaceuticals, Inc. 71
7.3.7 Salix Pharmaceuticals, Ltd. Enters into License Agreement with Merck & Co, Inc. 71
7.3.8 Amgen Enters into Licensing Agreement with Cytokinetics 71
8 Appendix 72
8.1 All Pipeline Drugs by Phase 72
8.1.1 Preclinical 72
8.1.2 Pre-registration 76
8.1.3 Phase I 76
8.1.4 Phase II 78
8.1.5 Phase III 80
8.2 Market Forecasts to 2019 81
8.2.1 Global 81
8.2.2 Australia 82
8.2.3 China 83
8.2.4 Japan 84
8.2.5 India 85
8.3 Market Definitions 86
8.4 Abbreviations 86
8.5 Sources 88
8.6 Research Methodology 89
8.6.1 Coverage 89
8.6.2 Secondary Research 89
8.6.3 Primary Research 90
8.6.4 Therapeutic Landscape 90
8.6.5 Geographical Landscape 93
8.6.6 Pipeline Analysis 93
8.7 Expert Panel Validation 93
8.8 Contact Us 93
8.9 Disclaimer 93